title: Marked regression of myelofibrosis during reduced-dose dasatinib treatment in chronic myelogenous leukemia in accelerated phase.
authors.affiliation: a Department of Internal Medicine III , Hematology & Oncology, University Hospital of Regensburg , Regensburg , Germany.
authors.forename: Roland Christian
authors.initials: RC
authors.lastname: Schelker
authors.affiliation: b Department of Pathology , University Hospital of Regensburg , Regensburg , Germany.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Huber
authors.affiliation: a Department of Internal Medicine III , Hematology & Oncology, University Hospital of Regensburg , Regensburg , Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Herr
authors.affiliation: a Department of Internal Medicine III , Hematology & Oncology, University Hospital of Regensburg , Regensburg , Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Vogelhuber
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001853:Bone Marrow / Q000473:pathology; D000069439:Dasatinib / Q000008:administration & dosage*; D006801:Humans; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069439:Dasatinib